IPSC (Century Therapeutics) Short-Term Capital Lease Obligation : $3.76 Mil (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Century Therapeutics Short-Term Capital Lease Obligation?

Century Therapeutics's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2024 was $3.76 Mil.

Century Therapeutics's quarterly Short-Term Capital Lease Obligation increased from Mar. 2024 ($2.22 Mil) to Jun. 2024 ($3.66 Mil) and increased from Jun. 2024 ($3.66 Mil) to Sep. 2024 ($3.76 Mil).

Century Therapeutics's annual Short-Term Capital Lease Obligation declined from Dec. 2021 ($0.62 Mil) to Dec. 2022 ($0.48 Mil) but then increased from Dec. 2022 ($0.48 Mil) to Dec. 2023 ($1.51 Mil).

Century Therapeutics Short-Term Capital Lease Obligation Historical Data

The historical data trend for Century Therapeutics's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Century Therapeutics Short-Term Capital Lease Obligation Chart

Century Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.24

0.62

0.48

1.51

Century Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial															2.04	1.51	2.22	3.66	3.76

Century Therapeutics Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Century Therapeutics Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Century Therapeutics's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Century Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Century Therapeutics Inc (NAS:IPSC) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

25 N 38th Street, 11th Floor, Philadelphia, PA, USA, 19104

Website

https://www.centurytx.com

Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.

Executives

Adrienne Farid	officer: Chief Operations Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Douglas Carr	officer: VP of Finance and Operations	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Daphne Quimi	director	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Gregory Russotti	officer: Chief Technology Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Luis Borges	officer: Chief Scientific Officer	TWO CORPORATE DRIVE, C/O FIVE PRIME THERAPEUTICS, INC., SOUTH SAN FRANCISCO CA 94080
Timothy P Walbert	director	1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Versant Venture Capital Vi, L.p.	10 percent owner	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Joseph Jimenez	director	ADITUM BIO, 1111 BROADWAY, STE. 1300, OAKLAND CA 94607
Eli Casdin	director	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Cynthia M Butitta	director	3165 PORTER DRIVE, PALO ALTO CA 94304
Kimberly Blackwell	director	C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Rizzuto Carlo	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Alessandro Riva	director	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104
Hyam Levitsky	officer: President of R&D	C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Osvaldo Flores	officer: Chief Executive Officer	C/O CENTURY THERAPEUTICS, INC., 3675 MARKET STREET, PHILADELPHIA PA 19104